pI: 9.5409 |
Length (AA): 569 |
MW (Da): 66929 |
Paralog Number:
0
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 3 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
1 | 139 | 4uos (A) | 34 | 166 | 23.00 | 0.69 | 0.5 | 0.494688 | -0.67 |
9 | 567 | 4hat (C) | 484 | 1023 | 11.00 | 0 | 0.84 | 1.02073 | 0.05 |
22 | 486 | 2g7n (A) | 4 | 419 | 13.00 | 0 | 0.87 | 0.632523 | 0.97 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 80-100% percentile | Female gametocyte. | Yeoh LM |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 60-80% percentile | Gametocyte, 22 hs Schizont. | Otto TD |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Lower 20-40% percentile | Erthyrocytic stages. | Yeoh LM |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Lower 0-20% percentile | Ookinete, 4 hs Ring, 16 hs Trophozoite, Male gametocyte. | Otto TD Yeoh LM |
Otto TD | A comprehensive evaluation of rodent malaria parasite genomes and gene expression. |
Yeoh LM | Comparative transcriptomics of female and male gametocytes in Plasmodium berghei and the evolution of sex in alveolates. |
Ortholog group members (OG5_129136)
Species | Accession | Gene Product |
---|---|---|
Drosophila melanogaster | Dmel_CG3121 | CG3121 gene product from transcript CG3121-RA |
Echinococcus granulosus | EgrG_000210100 | radial spoke head protein 4 A |
Echinococcus granulosus | EgrG_000461300 | radial spoke head protein 4 A |
Echinococcus multilocularis | EmuJ_000210100 | radial spoke head protein 4 A |
Echinococcus multilocularis | EmuJ_000461300 | radial spoke head protein 4 A |
Giardia lamblia | GL50803_16720 | Hypothetical protein |
Homo sapiens | ENSG00000104941 | radial spoke head 6 homolog A (Chlamydomonas) |
Homo sapiens | ENSG00000111834 | radial spoke head 4 homolog A (Chlamydomonas) |
Leishmania braziliensis | LbrM.29.0670 | flagellar radial spoke protein-like, putative |
Leishmania braziliensis | LbrM.13.0250 | flagellar radial spoke protein, putative |
Leishmania donovani | LdBPK_130290.1 | Flagellar radial spoke protein 4/6 |
Leishmania infantum | LinJ.29.0690 | flagellar radial spoke protein-like, putative |
Leishmania infantum | LinJ.13.0290 | flagellar radial spoke protein, putative |
Leishmania major | LmjF.29.0660 | flagellar radial spoke protein-like, putative |
Leishmania major | LmjF.13.0430 | flagellar radial spoke protein, putative |
Leishmania mexicana | LmxM.13.0430 | flagellar radial spoke protein, putative |
Leishmania mexicana | LmxM.08_29.0660 | flagellar radial spoke protein-like, putative |
Mus musculus | ENSMUSG00000040866 | radial spoke head 6 homolog A (Chlamydomonas) |
Mus musculus | ENSMUSG00000039552 | radial spoke head 4 homolog A (Chlamydomonas) |
Neospora caninum | NCLIV_033120 | GM16080, related |
Oryza sativa | 4342974 | Os07g0298900 |
Plasmodium berghei | PBANKA_0942300 | radial spoke head protein, putative |
Plasmodium falciparum | PF3D7_1104600 | radial spoke head protein, putative |
Plasmodium knowlesi | PKNH_0902200 | radial spoke head protein, putative |
Plasmodium vivax | PVX_090910 | hypothetical protein, conserved |
Plasmodium yoelii | PY02386 | Drosophila melanogaster GH13165p |
Schistosoma japonicum | Sjp_0053540 | Radial spokehead-like protein 1, putative |
Schistosoma mansoni | Smp_134660 | radial spokehead-l |
Schistosoma mansoni | Smp_057090 | radial spokehead-l |
Schmidtea mediterranea | mk4.001966.02 | Putative radial spokehead-l |
Schmidtea mediterranea | mk4.028952.00 | |
Schmidtea mediterranea | mk4.024656.00 | |
Schmidtea mediterranea | mk4.015823.01 | Putative radial spokehead-l |
Trypanosoma brucei gambiense | Tbg972.3.3990 | flagellar radial spoke protein-like, putative |
Trypanosoma brucei gambiense | Tbg972.11.5120 | flagellar radial spoke component, putative,Flagellar radial spoke protein 4, putative |
Trypanosoma brucei | Tb927.11.4480 | Flagellar radial spoke protein 4/6 |
Trypanosoma brucei | Tb927.3.3690 | flagellar radial spoke protein-like, putative |
Trypanosoma congolense | TcIL3000.11.4550 | Flagellar radial spoke protein 4/6 |
Trypanosoma congolense | TcIL3000_3_2390 | flagellar radial spoke protein-like, putative |
Trypanosoma cruzi | TcCLB.510149.120 | flagellar radial spoke protein-like, putative |
Trypanosoma cruzi | TcCLB.506989.70 | flagellar radial spoke protein-like, putative |
Trypanosoma cruzi | TcCLB.504089.50 | Flagellar radial spoke protein 4/6 |
Toxoplasma gondii | TGME49_233330 | radial spokehead family protein |
Trichomonas vaginalis | TVAG_182860 | flagellar radial spoke, putative |
Trichomonas vaginalis | TVAG_455950 | flagellar radial spoke, putative |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb927.3.3690 | Trypanosoma brucei | significant loss of fitness in bloodstream forms (3 days) | alsford |
Tb927.3.3690 | Trypanosoma brucei | significant loss of fitness in bloodstream forms (6 days) | alsford |
Tb927.3.3690 | Trypanosoma brucei | significant loss of fitness in procyclic forms | alsford |
Tb927.3.3690 | Trypanosoma brucei | significant loss of fitness in differentiation of procyclic to bloodstream forms | alsford |
Tb11.02.2060 | Trypanosoma brucei | significant loss of fitness in bloodstream forms (3 days) | alsford |
Tb11.02.2060 | Trypanosoma brucei | significant loss of fitness in bloodstream forms (6 days) | alsford |
Tb11.02.2060 | Trypanosoma brucei | no significant loss or gain of fitness in procyclic forms | alsford |
Tb11.02.2060 | Trypanosoma brucei | significant loss of fitness in differentiation of procyclic to bloodstream forms | alsford |
PBANKA_0942300 this record | Plasmodium berghei | Dispensable | plasmo |
TGME49_233330 | Toxoplasma gondii | Essentiality uncertain | sidik |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.